Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Biomedical Journal of Indonesia
Gerie Amarendra
Department of Internal Medicine, Faculty of Medicine, Universitas Trisakti, Jakarta Barat, Indonesia
Biochemistry, Genetics & Molecular Biology Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Potassium Competitive Acid Blockers: A New Paradigm For The Management of Stomach Acid Disorders Gerie Amarendra; Wawan Kurniawan; Mizanul Adli
Biomedical Journal of Indonesia Vol. 9 No. 2 (2023): Vol 9, No 2, 2023
Publisher : Fakultas Kedokteran Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bji.v9i2.164

Abstract

Proton pump inhibitors (PPIs) are the main therapy for stomach acid disorders to date. The disadvantage of PPI is the difficulty of controlling symptoms at night, such as tightness, chest pain, and coughing cough. Potassium competitive acid blockers (P-CAB) are a new class in the management of stomach acid disorders. Potassium competitive acid blockers work by a different mechanism, which binds non-covalently to H+/K+-ATPase. This mechanism results in a faster, stronger, and long-lasting suppression effect of gastric acid production. Besides being able to cure gastric complaints at night, P-CAB increases the success of Helicobacter pylori eradication. The safety of the use of this P_CAB drug, according to research is quite mild and acceptable. Currently, examples of P-CAB groups on the market are vonoprazan and tegoprazan. This narrative review is intended to provide further insight into this potassium competitive acid blocker (P-CAB) class of drugs.
Co-Authors Mizanul Adli Solly Aryza